Wall Street brokerages expect OncoCyte Corporation (NASDAQ:OCX) to announce earnings of ($0.10) per share for the current quarter, according to Zacks. Zero analysts have made estimates for OncoCyte’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.09). OncoCyte posted earnings of ($0.12) per share during the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The business is scheduled to issue its next earnings report on Tuesday, August 13th.

According to Zacks, analysts expect that OncoCyte will report full-year earnings of ($0.38) per share for the current financial year, with EPS estimates ranging from ($0.41) to ($0.34). For the next year, analysts expect that the business will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.53) to ($0.38). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for OncoCyte.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Tuesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.02.

Several research analysts recently issued reports on OCX shares. BidaskClub raised shares of OncoCyte from a “hold” rating to a “buy” rating in a report on Saturday. Chardan Capital restated a “buy” rating on shares of OncoCyte in a research report on Tuesday, April 2nd.

Shares of OncoCyte stock opened at $5.05 on Friday. OncoCyte has a 1 year low of $1.16 and a 1 year high of $6.92.

OncoCyte Company Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

See Also: Bond

Get a free copy of the Zacks research report on OncoCyte (OCX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.